17 Years
40 Years
Female
Polycystic Ovary Syndrome
Trial Information
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive
age with a probable prevalence of 5% to 10%. PCOS is characterized by chronic anovulation,
menstrual irregularities, evidence of hyperandrogenism (either clinical, manifested as
hirsutism, acne, male pattern balding, or biochemical, manifested by elevated serum adrenal
and/or ovarian androgen concentration). Fifty percent of all patients with PCOS are obese,
and the presence of obesity affects the clinical manifestations of PCOS. The underlying
pathogenic mechanisms appear to involve insulin resistance and hyperinsulinemia, the
magnitude of which is greater in obese than in non-obese women with PCOS.
Inclusion Criteria:
- 1. Oligomenorrhea ( less than 6 times spontaneous MC per year) or Amenorrhea. 2.
Hyperandrogenism (either clinical or biochemistry. 3. PCO by ultrasound. 4.After
menarche, before menopause.
Exclusion Criteria:
- 1. hormone therapy in the past 6 months. 2. Pregnancy in the past 6 months 3.Acute
illness found in the past 3 months. 4.Systemic disease including autoimmune disease,
malignancy, hepatic, renal or CVS disease, and ever received chemotherapy or
immunosuppressive agents.
Type of Study:
Observational
Study Design:
Observational Model: Defined Population, Observational Model: Natural History, Time Perspective: Cross-Sectional, Time Perspective: Prospective
Principal Investigator
Horng-Nerng Ho, M.D.
Investigator Role:
Study Director
Investigator Affiliation:
NTUH
Authority:
Taiwan: Department of Health
Study ID:
9361701094
NCT ID:
NCT00172523
Start Date:
October 2004
Completion Date:
August 2005
Related Keywords:
- Polycystic Ovary Syndrome
- Polycystic Ovary Syndrome
Name | Location |
|---|
